Successful exit for HTGF: Health App provider Sonormed becomes part of the InfectoPharm Group

January 23, 2025

Bonn, 23 January 2025 – InfectoPharm Arzneimittel und Consilium GmbH, a family-owned company specialising in the discovery and further development of pharmaceuticals, is acquiring HTGF portfolio company Sonormed GmbH. Sonormed produces digital health applications (DiGAs) and is a digital health pioneer as the developer of the first app on prescription. High-Tech Gründerfonds (HTGF) was the first institutional investor to invest in Sonormed in 2014 and has closely supported the successful development of the digital health company. As part of the transaction, HTGF is selling its shares.

Digital help for tinnitus patients
Sonormed from Hamburg specialises in digital medical products on prescription. A unique infrastructure was established with Tinnitracks, the first app on prescription in Germany. The next step was taken with the approval of the DiGA “Meine Tinnitus App” in March 2022. A clinical study proved the significant reduction in direct tinnitus and the associated everyday stress. It led to permanent listing as a DiGA by the Federal Institute for Drugs and Medical Devices (BfArM) and thus permanent reimbursement by the statutory health insurance funds. This gave millions of tinnitus sufferers in Germany access to this unique form of therapy. This digital therapy helps sufferers to reduce their stress, find a better way of dealing with their own tinnitus and regain a better quality of life in the long term.

InfectoPharm and Sonormed are now joining forces to jointly drive the development of innovative digital health solutions and support tinnitus patients with the best possible care. Sonormed co-founder and CEO Jörg Land will continue to be responsible for the “Meine Tinnitus App” product within InfectoPharm.

The Sonormed team has developed a compelling product with “Meine Tinnitus App”. It is therefore an important step, together with InfectoPharm, to drive forward the further expansion of our DiGA and digital care in general.

Jörg Land, co-founder and CEO of Sonormed

With the integration of Sonormed into our group, we are taking a significant step towards expanding our portfolio in ENT medicine. We are convinced that we will not only be able to improve the care of tinnitus patients, but also increase their quality of life in the long term. The quality of the product and the team have convinced us.

Philipp Zöller, Managing Director at InfectoPharm Arzneimittel und Consilium GmbH

Sonormed has impressively demonstrated that with outstanding technology, perseverance and professional management, it is possible to develop capital-efficient and successful digital health applications. This acquisition is a clear ray of hope in the current market environment for DiGAs and illustrates the great potential that digital therapies still have for patients. We wish InfectoPharm and Sonormed every success on their joint journey.

Kay Balster, Principal at High-Tech Gründerfonds


About InfectoPharm Arzneimittel und Consilium GmbH
InfectoPharm Arzneimittel und Consilium GmbH specialises in the new and further development of medicinal products. For more than 35 years, the family-run German company has made a name for itself as a courageous pioneer in the industry. The portfolio currently comprises around 130 preparations with numerous innovations for the fields of paediatrics, infectiology, pneumology, dermatology, allergology and ENT medicine, which are increasingly attracting international attention. The consilium service is available free of charge to healthcare professionals as a product-neutral advisory and knowledge transfer service.

About Sonormed GmbH
Sonormed GmbH develops new technologies in the field of digital audiology and was founded in Hamburg in 2012. The company has a unique infrastructure that meets the requirements for medical devices and those of health insurance companies. Sonormed works together with well-known industrial companies, insurance companies and research institutions.

About HTGF – High-Tech Gründerfonds
HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved over 190 successful exits.  
Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
For more information, please visit HTGF.de or follow us on LinkedIn.  

Media contact
High-Tech Gründerfonds Management GmbH
Tobias Jacob, Senior Marketing & Communications
T.: +49 228 – 82300 –
t.jacob@htgf.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

Press
6. February 2025

Modular. Data-driven. Connected. Avelios Medical secures €30 million from Sequoia Capital for its next-generation hospital information system

The funding round is one of the largest Series A rounds in digital health in recent months. Avelios Medical offers the HIS of the future: designed around hospital workflows, powered by modular microservices, and based on structured data to enable AI-driven care. Leading hospitals are successfully using Avelios Medical’s software as the modern alternative in the HIS market. Munich, February 6, 2025 – Avelios Medical, provider of a modern hospital information system (HIS), h
 
Press
4. February 2025

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others Akribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion Experienced team with a background in biotechnology and company building led by co-CEO’s Dr. Michael Krohn and Lukas Linnig Dr. Paul Scholz, the principal inventor of G-dase E technology, joins as Head of Research and Development Akribion Therapeutics (“Akribion”), the earl